Rivahib^®

Rivahib^® contains the active ingredient rivaroxaban.

Rivahib^® 10 mg is used in adults:

– to prevent the formation of blood clots in the veins in patients who underwent surgery to replace a hip or knee; This medicinal product is prescribed because there is an increased risk of blood clot formation after an operation.

– to treat blood clots in the veins of the legs (deep vein thrombosis, DVT) and the blood vessels of the lungs (pulmonary embolism) as well as to prevent DVT and pulmonary embolism from recurring.

Rivahib^® 15 mg and 20 mg are used in adults:

– to prevent stroke (blood clot in the brain) and other blood vessels in the body when patients suffer from a form of cardiac arrhythmia called non-valvular atrial fibrillation (not caused by heart valve disease).

– to treat blood clots in the veins of the legs (deep vein thrombosis, DVT) and the blood vessels of the lungs (pulmonary embolism) as well as to prevent DVT and pulmonary embolism from recurring.

Rivahib^® 15 mg and 20 mg are used in children and adolescents under 18 years of age and weighing 30 kg or more:

– for the treatment of blood clots and prevention of recurrence of blood clots in the veins or blood vessels of the lungs after at least 5 days of initial treatment with injectable medicines for the treatment of blood clots.

Rivahib^® belongs to a group of medicines called antithrombotic agents. It works by inhibiting a blood clotting factor (factor Xa), thereby reducing the blood’s tendency to form blood clots.